Sia Daneshmand, M.D.
@siadaneshmand
Professor of Urology and Oncology (Clinical Scholar)
Director of Urologic Oncology
Director of Clinical Research
Urologic Oncology Fellowship Director
USC
ID:49533860
22-06-2009 04:17:54
707 Tweets
3,2K Followers
587 Following
YES, our team has been busy
Third paper to announce in 7 days
Our FIRST take on automating suturing skills assessment #SurgicalAI
FREE access rdcu.be/cYhrS
Funded by National Cancer Institute #R01 #DeepStitch
Prof. Anima Anandkumar Caltech De-An Huang NVIDIA AI
๐ Enfortumab vedotin + pembro as 1st-line tx for metastatic #UrothelialCancer yields response rate of 73.3%, duration of response 25.6 mo, overall survival 26.1 mo.ย ๐ fal.cn/3sEjU #JCO #blcsm #kcsm #gucsm Jonathan Rosenberg MD
Western Section AUA will host Women of the WSAUA in Kauai. ๐ ALL are welcome! Thank you, @preyblat, for spearheading this wonderful initiative! Sia Daneshmand, M.D. #ChrisPorter Christopher J. Kane Christopher Amling Amer. Urol. Assn. Kaiser Permanente Urology Casey Seideman MD
Iranian women are among the most educated and accomplished around the world. Help support the movement #mahsaamini #womenofiran #womensrights #iranpotests instagram.com/p/CjN0fKorqXJ/โฆ
Indeed well done trial. ๐ Several caveats to consider: #1 Vast majority IR highlighted by Saum Ghodoussipour #2 low CIS (11-13%) where BL best. #3 wide CI 0.69-1.28 #4 BL performed once at start. RFS curves in favor of BL up to 12-15 mos. Would RFS have diverged if f/u also done with BL?
Oldies but goodies. Stephen Boorjian, MD Mayo Clinic Urology USC series ncbi.nlm.nih.gov/pubmed/15538242 Mayo series. ncbi.nlm.nih.gov/pubmed/17631342 Some with limited nodes can be cured. We still see them in clinic!
DrBagrodia Sam S. Chang MD, MBA Sia Daneshmand, M.D. Anne Schuckman Amir Salmasi Eugene Pietzak Solomon Woldu Jay B. Shah Angie Smith Agree with DrBagrodia If extraperitoneal, just a cath until healed (confirm with cystogram). If resection was incomplete, go back and finish resection once healing is complete.
I donโt keep them abx just cover when the cath is removed.
Sumanta Pal Uromigos ๐alison birtle Tom Powles Neeraj Agarwal Brian Rini, MD Sia Daneshmand, M.D. Vadim Koshkin MD Very interesting indeed! An unmet need to do novel biomarker-driven adjuvant trials like PROOF-302 trial exploring the role of FGFR inhibition in pts with FGFR3 alterations.
clinicaltrials.gov/ct2/show/NCT04โฆ
Really to proud to be a speaker at the first #sogocon meeting in Bangalore, #india , next week.
๐ฎ๐ณ๐ฎ๐ณ๐ฎ๐ณ๐ฎ๐ณ๐ฎ๐ณ๐ฎ๐ณ๐ฎ๐ณ๐ฎ๐ณ๐ฎ๐ณ๐ฎ๐ณ
Unfortunately, Virtual ๐.
๐๐Great expert panel Vedang Murthy Amar Kishan Sia Daneshmand, M.D. Prof Ananya๐
โ๏ธThanks a lot Vedang Murthy for this invitation.